AMRI extends ABA contract with GE Healthcare to 2016
Intermediate will be produced at large-scale manufacturing subsidiary in Rensselaer
AMRI has extended its commercial supply relationship with GE Healthcare for Aminobisamide Hydrochloride (ABA), an intermediate material used in diagnostic imaging agents, to 2016.
Under the terms of the agreement, the US contract research and manufacturing organisation will produce ABA at its large-scale manufacturing subsidiary in Rensselaer, New York State until 31 December 2016.
The agreement replaces the existing supply contract between GE and AMRI that has been in place since 2005.
Thomas D’Ambra, AMRI’s chairman, CEO and president said: “The ABA product relationship with GE Healthcare has been an important one for AMRI since the acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement. We continue to be pleased with the progress that we are making in our large scale manufacturing business segment, the largest component of which is our Rensselaer site.
‘We are adding new customers and new products at this facility, along with continuing the long-term relationships, like the one with GE Healthcare, that have formed the basis of our revenue stream.
‘The extension of this key, long term agreement provides a consistent and high quality revenue source for this business unit through to 2016.’